Thursday, June 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Sandia Seeks POC Diagnostics Technology Transfer

by Global Biodefense Staff
May 17, 2012

Sandia National Laboratories is seeking one or more business partners to commercialize a technology they have developed for point-of-care diagnostics based on centrifugal microfluidics.

The technology transfer opportunity, called SpinDx, is based on an innovative technique for conducting simultaneous multiplexed immunoassays and white blood cell counts from a single finger prick of whole blood.   The technique is based on sedimentation principles within a disposable microfluidic disk, in which all sample processing and detection is automated by centrifugal force.

Sandia describes SpinDx as being highly flexible, enabling customized assay development and consolidated disk prototyping with rapid turnaround time.  Other listed features include:

• Multiplexed: Up to 64 parallel assays from a single sample
• Speed: <15 min sample-to answer
• Minimally-invasive: <20μL sample input (i.e., finger puncture whole blood sample)
• Disposable: Single-use disks pre-loaded with all reagents for off-the-shelf processing
• Simple/robust: Based on well-established principles requiring unsophisticated instrumentation

Commercial licensees will have the opportunity to obtain a license to the intellectual properties for reasonable compensation. It is expected that the any company that works with Sandia to develop the SpinDx technology will incorporate it into a commercial product. Further details are available under Solicitation Number: 12-373. Additional opportunities for licensing are available at the Sandia Licensing and Technology Transfer website.

Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy’s National Nuclear Security Administration under contract DE-AC04-94AL85000.

View Profile: Sandia National Laboratories

Tags: MultiplexPOC Diagnostics

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC